Group One Trading’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-2,600
| Closed | -$57.6K | – | 8359 |
|
|
2022
Q3 | $51K | Buy |
+2,600
| New | +$52.1K | ﹤0.01% | 5399 |
|
|
2020
Q4 | – | Sell |
-2,366
| Closed | -$29K | – | 7172 |
|
|
2020
Q3 | $29K | Buy |
+2,366
| New | +$31.7K | ﹤0.01% | 4963 |
|
|
2020
Q1 | – | Sell |
-118
| Closed | -$1.4K | – | 5916 |
|
|
2019
Q4 | $1K | Sell |
118
-38
| -24% | -$206 | ﹤0.01% | 5017 |
|
|
2019
Q3 | $1K | Sell |
156
-135
| -46% | -$896 | ﹤0.01% | 5032 |
|
|
2019
Q2 | $2K | Buy |
291
+40
| +16% | +$609 | ﹤0.01% | 4780 |
|
|
2019
Q1 | $5K | Buy |
251
+172
| +218% | +$3K | ﹤0.01% | 4452 |
|
|
2018
Q4 | $1K | Buy |
+79
| New | +$1.58K | ﹤0.01% | 4761 |
|
|
2018
Q1 | – | Sell |
-440
| Closed | -$16.1K | – | 5438 |
|
|
2017
Q4 | $16K | Buy |
440
+220
| +100% | +$9.61K | ﹤0.01% | 4230 |
|
|
2017
Q3 | $12K | Buy |
+220
| New | +$13.1K | ﹤0.01% | 4246 |
|
|
2017
Q1 | – | Sell |
-76
| Closed | -$4K | – | 5120 |
|
|
2016
Q4 | $4K | Buy |
76
+40
| +111% | +$2.42K | ﹤0.01% | 4162 |
|
|
2016
Q3 | $2K | Sell |
36
-1,700
| -98% | -$120K | ﹤0.01% | 4390 |
|
|
2016
Q2 | $98K | Sell |
1,736
-2,356
| -58% | -$143K | ﹤0.01% | 2879 |
|
|
2016
Q1 | $262K | Buy |
4,092
+3,001
| +275% | +$243K | ﹤0.01% | 2148 |
|
|
2015
Q4 | $154K | Buy |
1,091
+371
| +52% | +$50.4K | ﹤0.01% | 2683 |
|
|
2015
Q3 | $70K | Buy |
+720
| New | +$85.7K | ﹤0.01% | 3308 |
|
Group One Trading's KDNY Position: Q4 2022 in Review
Group One Trading sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2022, closing a stake of 2,600 shares — an estimated $57.6K sold.
Group One Trading first reported a position in KDNY in Q3 2015 and held it in 15 quarters. The position peaked at $262K in Q1 2016. 155 funds tracked by Wall St. Rank hold KDNY as of Q4 2022.
- Group One Trading reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
- Group One Trading sold 2,600 Chinook Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $57.6K.
- Group One Trading first reported a position in Chinook Therapeutics, Inc. Common Stock in Q3 2015 and held it in 15 quarters.
- Group One Trading's Chinook Therapeutics, Inc. Common Stock position peaked at $262K in Q1 2016.
- 155 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2022.
Based on Group One Trading's 13F filing for Q4 2022, filed 9 Feb 2023.